R
Rick Chappell
Researcher at University of Wisconsin-Madison
Publications - 260
Citations - 14738
Rick Chappell is an academic researcher from University of Wisconsin-Madison. The author has contributed to research in topics: Radiation therapy & Population. The author has an hindex of 63, co-authored 245 publications receiving 13610 citations. Previous affiliations of Rick Chappell include University of Texas at Austin & University of Chicago.
Papers
More filters
Journal ArticleDOI
Is α/β for prostate tumors really low?
TL;DR: All the estimates point toward low values of α/β, at least as low as the estimates of Brenner and Hall, and possibly lower than the expected values of about 3 Gy for late complications.
Journal ArticleDOI
A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis
Richard M. Auchter,John Lamond,Eben Alexander,John M. Buatti,Rick Chappell,William A. Friedman,Timothy J. Kinsella,Allan B. Levin,William R. Noyes,Christopher J. Schultz,Jay S. Loeffler,Minesh P. Mehta +11 more
TL;DR: The RS in conjunction with WBRT for single brain metastasis can produce substantial functional survival, especially in patients with good performance status and without extracranial metastasis, which strongly suggest that a randomized trial to compare RS with surgery is warranted.
Journal ArticleDOI
A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases.
Penny K. Sneed,John H. Suh,Steven J. Goetsch,Seema N Sanghavi,Rick Chappell,John M. Buatti,William F. Regine,Eduardo Weltman,Vernon King,John C. Breneman,Paul W. Sperduto,Minesh P. Mehta +11 more
TL;DR: Omission of up-front WBRT does not seem to compromise length of survival in patients treated with RS for newly diagnosed brain metastases, and there was no survival difference comparing RS alone initially to RS + up- front W BRT.
Journal ArticleDOI
Sequential designs for phase I clinical trials with late-onset toxicities.
Ying Kuen Cheung,Rick Chappell +1 more
TL;DR: A simulation study shows the method's accuracy and safety are comparable with CRM's while the former takes a much shorter trial duration: a trial that would take up to 12 years to complete by the CRM could be reduced to 2–4 years by the TITE‐CRM.
Journal ArticleDOI
Preliminary Results of a Randomized Study on Therapeutic Gain by Concurrent Chemotherapy for Regionally-Advanced Nasopharyngeal Carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group
Anne W.M. Lee,Wai Hon Lau,Stewart Y. Tung,Daniel T.T. Chua,Rick Chappell,Luying Xu,Lillian L. Siu,W.M. Sze,To-Wai Leung,Jonathan S.T. Sham,Roger K.C. Ngan,Stephen C.K. Law,T. K. Yau,Joseph S. K. Au,Brian O'Sullivan,Ellie S.Y. Pang,Gordon K.H. Au,Joseph Lau +17 more
TL;DR: Preliminary results confirmed that CRT could significantly improve tumor control, particularly at locoregional sites, however, there was significant increase in the risk of toxicities and no early gain in overall survival.